Ownership and insider activity for Ovid Therapeutics Inc. (OVID): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infa...
Price
| Price | $2.68 |
| Market Cap | $500M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51.9M | $87.1M | $36.5M | $41.9M | $72.0M | $187.8M | $44.9M | $27.0M | $26.3M | $13.2M |
| Short-term Investments | 0 | 0 | $5.0M | $34.8M | 0 | 0 | $84.1M | $78.8M | $26.8M | $56.5M |
| Receivables | $7369 | 0 | 0 | $1.1M | $141763 | 0 | 0 | 0 | 0 | 0 |
| Inventory | $242673 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $52.4M | $88.6M | $44.3M | $79.8M | $74.8M | $190.5M | $131.4M | $109.6M | $55.9M | $90.4M |
| Property, Plant & Equipment | $43591 | $51775 | $69867 | $68363 | $135620 | $242757 | $16.1M | $14.7M | $13.2M | 0 |
| Goodwill | 0 | 0 | 0 | -$247 | $100 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $110074 | $124194 | $391872 | $467247 | $318900 | $164000 | $222100 | $200000 | $92000 | 0 |
| Total Assets | $53.0M | $89.5M | $47.6M | $80.8M | $75.9M | $194.5M | $155.3M | $144.0M | $92.2M | $150.9M |
| Accounts Payable | $857169 | $2.0M | $3.8M | $3.3M | $5.4M | $7.1M | $2.0M | $3.7M | $3.2M | $2.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.7M | $6.0M | $8.8M | $10.5M | $22.1M | $14.8M | $7.0M | $11.5M | $10.5M | $8.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $3.7M | $6.0M | $8.8M | $10.8M | $32.3M | $14.8M | $23.0M | $56.2M | $23.9M | $20.3M |
| Retained Earnings | -$61.8M | -$100.7M | -$152.7M | -$213.2M | -$294.2M | -$171.4M | -$225.5M | -$277.9M | -$304.3M | -$321.7M |
| Total Equity | $49.3M | $83.4M | $38.8M | $70.0M | $43.6M | $179.7M | $132.3M | $87.8M | $68.2M | $130.7M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | $16.5M | $16.0M | $14.8M | $13.4M |
| Net Debt | -$51.9M | -$87.1M | -$41.5M | -$76.7M | -$72.0M | -$187.8M | -$112.5M | -$89.8M | -$38.3M | -$56.2M |
| Working Capital | $48.7M | $82.6M | $35.4M | $69.3M | $52.8M | $175.7M | $124.4M | $98.1M | $45.4M | $82.2M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 12.39 |
Profitability
| Return on Equity | -23.64% |
| Return on Invested Capital | -26.11% |
| Return on Assets | -14.87% |
| Gross Margin | 100.00% |
| Operating Margin | -3686.67% |
| Net Margin | -2178.90% |
Related companies: CLNN · CNTB · CNTX · IFRX · IMA · KLRS · MGNX
Explore sector: Healthcare · Biotechnology
More sections of OVID: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks